Skip to main content

Advertisement

SpringerLink
Log in

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

After the front-line platinum-based regimens including concurrent chemoradiotherapy (CCRT) in patients with advanced or recurrent cervical cancer, platinum-based regimens are often used again.

Patients and methods

We retrospectively studied the predictors of response to second platinum therapy and prognostic factors of survival of 65 women who had received ≥2 platinum-based regimens in order to evaluate the effects of platinum-free interval (PFI), i.e., the interval between the platinum therapies.

Results

The median survival and PFI were 11.0 and 11.1 months, respectively. The response rate was 42% overall and 36% in the 36 patients who had received CCRT. The response rate increased in parallel with the length of the PFI. Multivariate analyses showed a PFI for ≥12 months (odds ratio [OR] = 0.20), a PS of 0 (OR = 0.16) and a maximum tumor diameter ≤30 mm (OR = 0.18) were predictive of response. Multivariate analyses also revealed a PFI for ≥6 months (hazard ratio [HR] = 0.44) and a PS of 0 (HR = 0.30) were prognostic of survival.

Conclusion

Our exploratory study demonstrated that PFI has both predictive and prognostic value for second platinum therapy in patients with advanced or recurrent cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Berek JS, Neville Hacker F (2005) Practical gynecologic oncology. Lippincott Williams & Wilkins, New York

    Google Scholar 

  3. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J (1981) Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Cancer 48:899–903

    Article  PubMed  CAS  Google Scholar 

  4. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS (1990) A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a southwest oncology group study. Gynecol Oncol 39:332–336

    Article  PubMed  CAS  Google Scholar 

  5. Arseneau J, Blessing JA, Stehman FB, McGehee R (1986) A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a gynecologic oncology group study). Invest New Drugs 4:187–191

    PubMed  CAS  Google Scholar 

  6. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. A gynecologic oncology group study. J Clin Oncol 14:792–795

    PubMed  CAS  Google Scholar 

  7. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15:625–631

    PubMed  CAS  Google Scholar 

  8. Sutton GP, Blessing JA, Adcock L, Webster KD, DeEulis T (1989) Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A gynecologic oncology group study. Invest New Drugs 7:341–343

    Article  PubMed  CAS  Google Scholar 

  9. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 23:4626–4633

    Article  PubMed  CAS  Google Scholar 

  10. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119

    Article  PubMed  CAS  Google Scholar 

  11. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic oncology group study. J Clin Oncol 27:4649–4655

    Article  PubMed  CAS  Google Scholar 

  12. Long HJ III (2007) Management of metastatic cervical cancer: review of the literature. J Clin Oncol 25:2966–2974

    Article  PubMed  CAS  Google Scholar 

  13. Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S (2003) Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 90:177–180

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Grants for Cancer Clinical Research (63) from Ministry of Health, Labor and Welfare, Japan.

Author information

Authors and Affiliations

  1. Breast and Medical Oncology Division, National Cancer Center Hospital Tokyo, Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan

    Maki Tanioka, Noriyuki Katsumata, Kan Yonemori, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Masashi Ando & Yasuhiro Fujiwara

  2. Medical Oncology Division, Hyogo Cancer Center, Hyogo, Japan

    Maki Tanioka

  3. Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, Hyogo, 673-8558, Japan

    Maki Tanioka

Authors
  1. Maki Tanioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noriyuki Katsumata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kan Yonemori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsutomu Kouno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chikako Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masashi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasuhiro Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maki Tanioka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanioka, M., Katsumata, N., Yonemori, K. et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol 68, 337–342 (2011). https://doi.org/10.1007/s00280-010-1494-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1494-7

Keywords

Search

Navigation